#China #Shanghai #biotechnology #Harbour BioMed #Dr. Adam Zong

Harbour BioMed Appoints Dr. Adam Zong as President

In a significant development for the biopharmaceutical sector, Harbour BioMed, a renowned global entity specialized in discovering and developing novel antibody therapeutics, has officially announced the appointment of Dr. Adam Zong as its new President. This strategic move is expected to bolster the company’s internal product pipeline and propel its overall portfolio strategy forward.

Dr. Zong, who will operate from the company's Shanghai office, comes to Harbour BioMed with over two decades of extensive experience in the biopharmaceutical industry. His career showcases an impressive history of leadership across a variety of international organizations where he has established a robust track record in portfolio strategy, commercial operations, and business development. Notably, before taking on this new role, Dr. Zong was the Principal Consultant at Arc Nouvel Clinical Development Consulting. He also played a pivotal role as the founding CEO of Hengrui Therapeutics U.S., leading the company’s global expansion.

Dr. Zong’s previous positions at notable multinational pharmaceutical companies, such as Merck & Co., Bristol Myers Squibb, Schering-Plough, and Pfizer, further highlight his capability to manage global franchises and oversee expansive commercial portfolios. His expertise in initiating high-stakes business development and licensing agreements will be a tremendous asset to Harbour BioMed as it seeks to advance its innovative products in immunology, oncology, and other therapeutic areas.

The Founder, Chairman, and CEO of Harbour BioMed, Dr. Jingsong Wang, expressed enthusiasm about Dr. Zong's arrival, stating, “We are very pleased to welcome Dr. Adam Zong to our executive team. His extensive leadership experience across global biopharma organizations and his strong track record in portfolio strategy and business development will be invaluable as we advance our innovative pipeline.” Dr. Wang emphasized their collective goal to strengthen the portfolio further and expand global partnerships.

In response to his new role, Dr. Zong reflected, “I am thrilled to join Harbour BioMed at such a pivotal moment. Under Jingsong's leadership, the Company has established itself as a world-class biotech leader, achieving remarkable successes. I intend to focus on developing a differentiated, high-value portfolio for Harbour's next phase of growth.” With his vision, Dr. Zong aims to cultivate innovative treatments that can redefine categories and provide transformative therapies to patients in need.

Dr. Zong holds a Ph.D. in Oncology and Virology from Rockefeller University, coupled with an MBA in Finance and Entrepreneurial Management from The Wharton School at the University of Pennsylvania, effectively blending scientific and business acumen.

About Harbour BioMed

Harbour BioMed (HKEX: 02142) stands at the forefront of biopharmaceutical advancements, committed to the discovery and development of groundbreaking antibody therapeutics in multiple medical fields. The company is currently expanding its robust pipeline through novel research and development capabilities, strategic global alliances in co-discovery, co-development efforts, and selective acquisitions.

Utilizing its proprietary antibody technology platform, Harbour Mice®, which excels in generating fully human monoclonal antibodies, the company aims to overcome traditional treatment limitations through pioneering approaches like HCAb-based immune cell engagers (HBICE®) and multi-specific medicine solutions. Additionally, the incorporation of AHU-mAtIx™ AI technology into its processes signals Harbour BioMed's commitment to leveraging artificial intelligence for innovative therapeutic development.

With this new leadership under Dr. Zong, Harbour BioMed is well-positioned to enhance its operational effectiveness and commitment to improving patient outcomes globally.